In accordance with unaltered CYP2C19 activity in patients with gastroesophageal reflux disease taking pantoprazole, weak inhibition by pantoprazole did not induce phenoconversion (Modak et al., 2016). This evidence concerns the gene CYP2C19 and gastroesophageal reflux disease.